New therapies on the horizon for hepatitis C: are we close?
New therapies on the horizon for hepatitis C: are we close?
复制标题
DOI：
10.1016/s1089-3261(02)00069-7
复制
发表时间：
2003-02-01
影响因子：
5.1
通讯作者：
Rice, Charles M
中科院分区：
文献类型：
--
作者：
De Francesco, Raffaele;Rice, Charles M
许多治疗丙型肝炎的新疗法正处于临床前和临床开发的各个阶段。如本文所述，这些包括基于核酸的方法（反义和核酶），小分子抑制剂的基本丙型肝炎病毒（HCV）编码的酶（蛋白酶，解旋酶和聚合酶），免疫调节和免疫治疗。随着HCV生命周期的更多细节被阐明，新的目标和方法将被发现。药物开发是困难的，昂贵的，总是令人痛苦的缓慢需要病人和他们的医生。尽管如此，针对丙型肝炎病毒已经做出了广泛的努力，并取得了实质性进展。新的HCV治疗方法的前景是光明的。
A myriad of new therapies for treating hepatitis C are in various stages of preclinical and clinical development. As reviewed here, these include nucleic acid-based approaches (antisense and ribozymes), small molecule inhibitors of essential hepatitis C virus (HCV)-encoded enzymes (protease, helicase, and polymerase), immune modulation, and immunotherapy. As more details of the HCV lifecycle are elucidated, new targets and approaches will be discovered. Drug development is difficult, expensive, and always agonizingly slow for patients in need and their physicians. Nonetheless, a broad effort has been mounted for HCV, and substantial progress has been achieved. The prospects for new HCV treatments are bright.